Aimia Valuation

Is 0UGP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0UGP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0UGP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0UGP's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0UGP?

Key metric: As 0UGP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0UGP. This is calculated by dividing 0UGP's market cap by their current revenue.
What is 0UGP's PS Ratio?
PS Ratio0.5x
SalesCA$437.10m
Market CapCA$235.72m

Price to Sales Ratio vs Peers

How does 0UGP's PS Ratio compare to its peers?

The above table shows the PS ratio for 0UGP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.7x
TET Treatt
1.7x7.2%UK£244.7m
SYNT Synthomer
0.1x5.0%UK£264.3m
IOF Iofina
0.9x9.8%UK£35.5m
CAR Carclo
0.2x7.0%UK£24.9m
0UGP Aimia
0.5x11.3%CA$235.7m

Price-To-Sales vs Peers: 0UGP is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.7x).


Price to Sales Ratio vs Industry

How does 0UGP's PS Ratio compare vs other companies in the GB Chemicals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
JMAT Johnson Matthey
0.2x-50.4%US$2.85b
SYNT Synthomer
0.1x5.0%US$335.05m
CAR Carclo
0.2x7.0%US$31.55m
HEIQ HeiQ
0.2xn/aUS$9.61m
0UGP 0.5xIndustry Avg. 1.3xNo. of Companies6PS01.22.43.64.86+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0UGP is good value based on its Price-To-Sales Ratio (0.5x) compared to the UK Chemicals industry average (1.3x).


Price to Sales Ratio vs Fair Ratio

What is 0UGP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0UGP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0UGP's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0UGP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$2.45
CA$4.13
+68.4%
3.0%CA$4.25CA$4.00n/a2
Aug ’25n/a
CA$4.25
0%
5.9%CA$4.50CA$4.00n/a2
Jul ’25n/a
CA$4.25
0%
5.9%CA$4.50CA$4.00n/a2
Jun ’25n/a
CA$4.25
0%
5.9%CA$4.50CA$4.00n/a2
May ’25n/a
CA$4.25
0%
5.9%CA$4.50CA$4.00n/a2
Apr ’25n/a
CA$4.25
0%
5.9%CA$4.50CA$4.00n/a2
Mar ’25CA$3.18
CA$5.13
+61.3%
2.4%CA$5.25CA$5.00n/a2
Feb ’25CA$3.31
CA$5.13
+54.8%
2.4%CA$5.25CA$5.00n/a2
Jan ’25n/a
CA$5.13
0%
2.4%CA$5.25CA$5.00n/a2
Dec ’24CA$3.01
CA$5.13
+70.5%
2.4%CA$5.25CA$5.00n/a2
Nov ’24n/a
CA$5.38
0%
2.3%CA$5.50CA$5.25n/a2
Oct ’24CA$2.94
CA$5.38
+82.8%
2.3%CA$5.50CA$5.25n/a2
Sep ’24n/a
CA$5.38
0%
2.3%CA$5.50CA$5.25n/a2
Aug ’24n/a
CA$5.63
0%
6.7%CA$6.00CA$5.25n/a2
Jul ’24n/a
CA$5.63
0%
6.7%CA$6.00CA$5.25n/a2
Jun ’24n/a
CA$5.63
0%
6.7%CA$6.00CA$5.25n/a2
May ’24n/a
CA$5.63
0%
6.7%CA$6.00CA$5.25n/a2
Apr ’24n/a
CA$5.63
0%
6.7%CA$6.00CA$5.25n/a2
Mar ’24n/a
CA$5.88
0%
2.1%CA$6.00CA$5.75CA$3.182
Feb ’24CA$3.54
CA$5.88
+66.0%
2.1%CA$6.00CA$5.75CA$3.312
Jan ’24n/a
CA$5.88
0%
2.1%CA$6.00CA$5.75n/a2
Dec ’23n/a
CA$5.88
0%
2.1%CA$6.00CA$5.75CA$3.012

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies